Hint mode is switched on Switch off
For swift navigation between sections

Vicore Pharma Holding
LEI 549300KTNBPTZLF01130

Organization name
Vicore Pharma Holding AB
Country name
Sweden
Country of registration
Sweden
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds
  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Quotes

Request sent
Access denied
Quotes provided by information providers are indicative in nature

Profile

Vicore Pharma Holding AB is a drug development company. The company's through is subsidiary is developing a new type of pharmaceutical compound, known as AT2R agonists, to stimulate the AT2 receptor within the Renin-Angiotensin system. Its lead drug candidate, C21, is the first small molecule compound in its class.

Awards

Documentation

Stocks

Public debt by currencies

Codes

  • LEI
    549300KTNBPTZLF01130
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • Organisationsnummer
    556680-3804
Registration is required to get access.